The shareholders of Median Technologies (ALMDT:PA) are invited to participate at the Shareholders’ Ordinary and Extraordinary General Meeting which will be held on Tuesday June 14, 2022, at 5:00 PM at PDGB, 174 avenue Victor Hugo – 75116 Paris.

Median has received the FDA’s feedback following the 513(g) regulatory submission for its iBiopsy® LCS CADe/CADx Software as Medical Device. Median will proceed through a 510(k) submission to obtain an FDA device clearance and market authorization, targeted for end 2023. On May 2, 2022, Median initiated a Q-submission process, composed of several submissions, to request feedback from the FDA on various topics such as the pivotal study protocols.

Record high revenue of €5.7 million in Q1 2022, up 9.2% compared with Q1 2021 – Further growth in the order backlog to €62.3 million as of March 31, 2022, up 18.4% compared with March 31, 2021- Revenue of €20.5 million as of December 31, 2021, up 52.4% compared to December 31, 2020 – Cash and cash equivalents of €33.1 million as of March 31, 2022

iBiopsy® Lung Cancer Screening (LCS) CADe/CADx outstanding performance reaches 94.7% sensitivity[2] at 93.3% specificity, based on a cohort of 1,760 patients. With such performance, iBiopsy® LCS CADe/CADx SaMD positions itself to dramatically increase the efficacy of lung cancer screening programs worldwide, which would facilitate saving the lives of millions.

Disclosure of total number of voting rights and number of shares in the capital as of February 28th, 2022, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.